Bone-targeted delivery of nanodiamond-based drug carriers conjugated with alendronate for potential osteoporosis treatment.
This paper describes the design of alendronate-conjugated nanodiamonds (Alen-NDs) and evaluation of their feasibility for bone-targeted delivery. Alen-NDs exhibited a high affinity to hydroxyapatite (HAp, the mineral component of bone) due to the presence of Alen. Unlike NDs (without Alen), Alen-NDs were preferentially taken up by MC3T3-E1 osteoblast-like cells, compared to NIH3T3 and HepG2 cells, suggesting their cellular specificity. In addition, NDs itself increased ALP activity of MC3T3-E1 cells, compared to control group (osteogenic medium) and Alen-NDs exhibited more enhanced ALP activity. In addition, an in vivo study revealed that Alen-NDs effectively accumulated in bone tissues after intravenous tail vein injection. These results confirm the superior properties of Alen-NDs with advantages of high HAp affinity, specific uptake for MC3T3-E1 cells, positive synergistic effect for ALP activity, and in vivo bone targeting ability. The Alen-NDs can potentially be employed for osteoporosis treatment by delivering both NDs and Alen to bone tissue.
Department of Biotechnology, The Catholic University of Korea, 43 Jibong-ro Wonmi-gu, Bucheon-si, Gyeonggi-do 420-743, Republic of Korea.
Tae-Kyung
TK
Ryu
Department of Biotechnology, The Catholic University of Korea, 43 Jibong-ro Wonmi-gu, Bucheon-si, Gyeonggi-do 420-743, Republic of Korea.
Rae-Hyoung
RH
Kang
Department of Biotechnology, The Catholic University of Korea, 43 Jibong-ro Wonmi-gu, Bucheon-si, Gyeonggi-do 420-743, Republic of Korea.
Ki-Young
KY
Jeong
Department of Biotechnology, The Catholic University of Korea, 43 Jibong-ro Wonmi-gu, Bucheon-si, Gyeonggi-do 420-743, Republic of Korea.
Dae-Ryong
DR
Jun
Division of Endocrinology and Metabolism, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 138-736, Republic of Korea.
Jung-Min
JM
Koh
College of Pharmacy, The Catholic University of Korea, 43 Jibong-ro Wonmi-gu, Bucheon-si, Gyeonggi-do 420-743, Republic of Korea.
Doyun
D
Kim
College of Pharmacy, The Catholic University of Korea, 43 Jibong-ro Wonmi-gu, Bucheon-si, Gyeonggi-do 420-743, Republic of Korea.
Soo Kyung
SK
Bae
Department of Biotechnology, The Catholic University of Korea, 43 Jibong-ro Wonmi-gu, Bucheon-si, Gyeonggi-do 420-743, Republic of Korea. Electronic address: choisw@catholic.ac.kr.
Sung-Wook
SW
Choi
D019386:Alendronate / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D000469:Alkaline Phosphatase / Q000378:metabolism; D000818:Animals; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D001842:Bone and Bones / Q000378:metabolism; D002460:Cell Line; D004337:Drug Carriers / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D017886:Durapatite / Q000737:chemistry; D005260:Female; D056945:Hep G2 Cells; D006801:Humans; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D058612:Nanodiamonds / Q000008:administration & dosage* / Q000737:chemistry; D010024:Osteoporosis / Q000188:drug therapy
D050071:Bone Density Conservation Agents; D004337:Drug Carriers; D058612:Nanodiamonds; D017886:Durapatite; D000469:Alkaline Phosphatase; D019386:Alendronate
Alendronate; Bone targeting; Nanodiamond; Osteoporosis